You heard it here first.


Our news

Bringing you the latest!


Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia

Corporate - Investors

15 November 2021

Phase 3 data of mdc-IRM, first product based on MedinCell’s […]

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia

Corporate - Investors

31 August 2021

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

Corporate - Investors

17 December 2020

MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations


9 December 2020



  • This field is for validation purposes and should be left unchanged.